Literature DB >> 21944479

Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect.

Michael Scully1, Chen Gang, Claire Condron, David Bouchier-Hayes, Anthony J Cunningham.   

Abstract

BACKGROUND: Polymorphoneutrophils (PMNs) are activated by inflammatory mediators following splanchnic ischemia/reperfusion (I/R), potentially injuring organs such as the lung. As a result, some patients develop respiratory failure following abdominal aortic aneurysm repair. Pulmonary cyclooxygenase (COX)-2 protects against acid aspiration and bacterial instillation via lipoxins, a family of potent anti-inflammatory lipid mediators. We explored the role of COX-2 and lipoxin A(4) in experimental I/R-mediated lung injury.
MATERIALS AND METHODS: Sprague-Dawley rats were assigned to one of the following five groups: (1) controls; (2) aortic cross-clamping for 45 min and reperfusion for 4 h (I/R group); (3) I/R and SC236, a selective COX-2 inhibitor; (4) I/R and aspirin; and (5) I/R and iloprost, a prostacyclin (PGI(2)) analogue. Lung injury was assessed by wet/dry ratio, myeloperoxidase (MPO) activity, and bronchoalveolar lavage (BAL) neutrophil counts. BAL levels of thromboxane, PGE(2), 6-keto-PGF(1)α (a hydrolysis product of prostacyclin), lipoxin A(4), and 15-epi-lipoxin A(4) were analyzed by enzyme immunoassay (EIA). Immunostaining for COX-2 was performed.
RESULTS: I/R significantly increased tissue MPO, the wet/dry lung ratio, and neutrophil counts. These measures were significantly further aggravated by SC236 and improved by iloprost. I/R increased COX-2 immunostaining and both PGE(2) and 6-keto-PGF(1α) levels in BAL. SC236 markedly reduced these prostanoids and lipoxin A(4) compared with I/R alone. Iloprost markedly increased lipoxin A(4) levels. The deleterious effect of SC236 and the beneficial effect of iloprost was associated with a reduction and an increase, respectively, in lipoxin A(4) levels.
CONCLUSIONS: Lipoxin A(4) warrants further evaluation as a mediator of COX-2 regulated lung protection.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21944479     DOI: 10.1016/j.jss.2011.02.020

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Lipoxin A4 protects rat skin flaps against ischemia-reperfusion injury through inhibiting cell apoptosis and inflammatory response induced by endoplasmic reticulum stress.

Authors:  Dawei Xin; Renfu Quan; Linru Zeng; Canda Xu; Yanghua Tang
Journal:  Ann Transl Med       Date:  2020-09

2.  Lipoxin A4 ameliorates ischemia/reperfusion induced spinal cord injury in rabbit model.

Authors:  Zhi-Qiang Liu; Hong-Bin Zhang; Jian Wang; Li-Jian Xia; Wei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 3.  Connexins and their channels in inflammation.

Authors:  Joost Willebrords; Sara Crespo Yanguas; Michaël Maes; Elke Decrock; Nan Wang; Luc Leybaert; Brenda R Kwak; Colin R Green; Bruno Cogliati; Mathieu Vinken
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-07-07       Impact factor: 8.250

Review 4.  Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice?

Authors:  Albert M Kroon; Jan-Willem Taanman
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

5.  Lipoxin a4 preconditioning and postconditioning protect myocardial ischemia/reperfusion injury in rats.

Authors:  Qifeng Zhao; Lan Shao; Xingti Hu; Guowei Wu; Jie Du; Jie Xia; Huixian Qiu
Journal:  Mediators Inflamm       Date:  2013-07-17       Impact factor: 4.711

6.  LipoxinA4 attenuates myocardial ischemia reperfusion injury via a mechanism related to downregulation of GRP-78 and caspase-12 in rats.

Authors:  Qifeng Zhao; Xingti Hu; Lan Shao; Guowei Wu; Jie Du; Jie Xia
Journal:  Heart Vessels       Date:  2013-10-16       Impact factor: 2.037

7.  Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study.

Authors:  Helene Haeberle; Stefanie Prohaska; Peter Martus; Andreas Straub; Alexander Zarbock; Gernot Marx; Manola Zago; Martin Giera; Michael Koeppen; Peter Rosenberger
Journal:  Trials       Date:  2020-03-04       Impact factor: 2.279

8.  COVID-19 acute respiratory distress syndrome: can iloprost have a role for the treatment?

Authors:  Alida Filippini; Claudio Bnà; Raffaello Bellosta; Roberto Bazzani; Luca Luzzani; Matteo Alberto Pegorer; Matteo Zandalasini; Michela Baldon; Manuela Codazzi; Tony Sabatini
Journal:  Respir Med Case Rep       Date:  2021-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.